首页> 外文学位 >Role of intracellular calcium(2+) in modulation of adiposity.
【24h】

Role of intracellular calcium(2+) in modulation of adiposity.

机译:细胞内钙(2+)在肥胖调节中的作用。

获取原文
获取原文并翻译 | 示例

摘要

Previous data from this laboratory demonstrated that increasing [Ca 2+]i stimulates lipogenesis and inhibits basal and agonist-stimulated lipolysis in both human and murine adipocytes. These data suggest that adipocyte [Ca2+]i is a logical target for pharmacological/nutritional regulation of adiposity. Accordingly, our studies were designed to (1) determine the role of [Ca2+]i in human adipocyte differentiation, an important contributor to adiposity, and (2) identify adipocyte targets which regulate [Ca2+]i and determine strategies for modulating these targets. We demonstrated that increasing preadipocyte [Ca2+]i in early stages of differentiation suppresses human adipocyte differentiation, while increasing [Ca2+] i late promotes human adipocyte differentiation. We identified a potential receptor target, the adipocyte sulfonylurea receptor (SUR), which mediates adipocyte [Ca2+]i signaling and corresponding increased lipogenesis and decreased lipolysis. Antagonism of this receptor reverses all these actions. We further extended this approach to dietary regulation of adipocyte [Ca2+]i. We demonstrated that 1α,25-(OH) 2-D3, which is regulated by dietary calcium, also stimulates adipocyte [Ca2+]i, promotes lipogenesis, and inhibits lipolysis, thereby resulting in triglyceride accumulation, via a rapid non-genomic action mediated by a putative membrane vitamin D receptor (mVDR). These actions can be mimicked by 1α,25-(OH)2-lumisterol 3, a specific agonist for mVDR, and completely prevented by 1β,25-(OH) 2-D3, a specific antagonist for the mVDR. Our data father demonstrated that suppression of 1α,25-(OH)2-D3 by increasing dietary calcium decreases adipocyte [Ca2+] i, stimulates lipolysis, inhibits lipogenesis in aP2-agouti transgenic mice and that dietary calcium not only attenuated diet-induced obesity but also accelerated weight loss and fat mass reduction secondary to caloric restriction. Notably, high calcium diets also increased white adipose tissue uncoupling protein 2 (UCP2) expression and core temperature. Subsequently, we demonstrated that 1α,25-(OH)2-D3 exerts an inhibitory effect on white adipocyte UCP2 expression and that this effect is mediated via a genomic action (nuclear vitamin D receptor; nVDR). Accordingly, these data demonstrate that SUR-mediated Ca2+ signaling and 1α,25-(OH) 2-D3-mediated genomic and non-genomic pathways play important roles in regulation of adipocyte lipid and energy metabolism and that antagonism of adipocyte [Ca2+]i by blocking these pathways may represent an effective approach for development of therapeutic intervention in obesity.
机译:该实验室以前的数据表明,增加[Ca 2 + ] i 可以刺激人和鼠脂肪细胞的脂肪生成,并抑制基础和激动剂刺激的脂肪分解。这些数据表明,脂肪细胞[Ca 2 + ] i 是肥胖的药理/营养调节的逻辑目标。因此,我们的研究旨在(1)确定[Ca 2 + ] i 在人脂肪细胞分化中的作用,这是肥胖的重要因素,并且(2)确定调节[Ca 2 + ] i 的脂肪细胞靶标,并确定调节这些靶标的策略。我们证明在分化的早期阶段增加前脂肪细胞[Ca 2 + ] i 抑制人脂肪细胞的分化,而增加[Ca 2 + ] < sub> i 晚期促进人类脂肪细胞分化。我们确定了潜在的受体靶标,脂肪细胞磺酰脲受体(SUR),它介导脂肪细胞[Ca 2 + ] i 信号传导,并相应地增加脂肪生成和减少脂解作用。该受体的拮抗作用逆转了所有这些作用。我们进一步将这种方法扩展到脂肪细胞[Ca 2 + ] i 的饮食调节中。我们证明了受饮食钙调节的1α,25-(OH) 2 -D 3 还可刺激脂肪细胞[Ca 2 + ] i ,通过假定的膜维生素D受体(mVDR)介导的快速非基因组作用,促进脂肪生成并抑制脂解作用,从而导致甘油三酸酯积累。这些作用可以通过1v,25-(OH) 2 -lumisterol 3 (一种mVDR的特异性激动剂)来模仿,而完全可以被1β,25-(OH)< sub> 2 -D 3 ,mVDR的特异性拮抗剂。我们的数据父亲证明,通过增加饮食中的钙来抑制1α,25-(OH) 2 -D 3 会降低脂肪细胞[Ca 2 + ] i 可以刺激脂解,抑制aP2-agouti转基因小鼠的脂肪生成,并且饮食中的钙不仅可以减轻饮食引起的肥胖,而且可以减轻体重,并限制热量导致脂肪减少。值得注意的是,高钙饮食还增加了白色脂肪组织解偶联蛋白2(UCP2)的表达和核心温度。随后,我们证明了1α,25-(OH) 2 -D 3 对白色脂肪细胞UCP2表达具有抑制作用,并且这种作用是通过基因组作用介导的(核维生素D受体; nVDR)。因此,这些数据证明了SUR介导的Ca 2 + 信号传导和1α,25-(OH) 2 -D 3 介导的基因组和非基因组途径在调节脂肪细胞脂质和能量代谢中起重要作用,并且通过阻断这些途径对脂肪细胞[Ca 2 + ] i 的拮抗作用可能代表了一种有效的方法。肥胖症治疗干预的发展。

著录项

  • 作者

    Shi, Hang.;

  • 作者单位

    The University of Tennessee.;

  • 授予单位 The University of Tennessee.;
  • 学科 Health Sciences Nutrition.; Biology Molecular.
  • 学位 Ph.D.
  • 年度 2001
  • 页码 416 p.
  • 总页数 416
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 预防医学、卫生学;分子遗传学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号